- AbbVie presents data from ABBV-400, ABBV-706, and Telisotuzumab vedotin trials
- Affimed Announces Positive Early Efficacy and PFS Results of AFM24-102 Study in EGFR WT NSCLC
- Affini-T Therapeutics to present poster on Ph 1 clinical trial evaluating AFNT-211 targeting KRAS G12V
- AffyImmune Announces Presentation on Affinity-Tuned CAR T Therapy AIC100
- Agendia Presents New Data on 3-Year Outcome of Chemotherapy Treatment in Patients with Early-Stage Breast Cancer
- Agendia Announces New Data Assessing the Immune Active State in HR+/HER2- Early-Stage Breast Cancer
- ALX Oncology Presents First Evorpacept Combination Data with an ADC from Ph 1 ASPEN-07 Trial in Patients with Advanced Bladder Cancer
- Amgen Presents Innovative Research From Its Oncology Portfolio
- Ankyra Therapeutics provides status update on ANK-101 Ph 1 ANCHOR trial
- Arvinas presents data of ARV-766 in prostate cancer and TACTIVE-K, a Phase 1b/2 trial with vepdegestrant + atirmociclib (PF-07220060)
- Aummune’s Poster to Highlight Ongoing Ph 1 Trial for AM003
- Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Ph 2 FELIX study of obe-cel for adult r/r B-ALL
- Black Diamond Therapeutics Presents Promising BDTX-1535 Data in rGBM Patients
- BriaCell Doubles PFS and Reports Clinical Benefit Data
- BRUKINSA Data Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
- Cantex Pharmaceuticals Announces Four Abstracts Featuring Azeliragon
- Corbus Pharma’s SYS6002 (CRB-701) Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors
- Dizal presented the latest data from WU-KONG1 Part B (WU-KONG1B) of sunvozertinib in R/R NSCLC with EGFR exon 20 insertion mutations (exon20ins)
- Eikon Therapeutics presents EIK1001 and EIK1001 data
- Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Ph 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors
- Enhertu demonstrated a mPFS of 13.2 months in HR+ve, HER2-low/ultralow metastatic breast cancer following one or more lines of endocrine therapy
- EpicentRx Announces Oral Presentation for TGF-β Ligand Trap, AdAPT-001
- First results from late-breaking Ph 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute SC amivantamab administration
- GenFleet Therapeutics Announces Efficacy & Safety Result from Ph 2 Trial for 1L NSCLC Treatment in KROCUS Study, fulzerasib in Combination with cetuximab
- Gilead And Arcus Announce Domvanalimab + Zimberelimab And Chemo Exceeded One Year Of mPFS As 1L Treatment For Upper GI Cancers
- Gilead And Arcus Announce Etrumadenant + Zimberelimab combo Significantly Reduced The Risk Of Death In 3L mCRC
- Grey Wolf Therapeutics Presents First Clinical Data for GRWD5769
- GSK presents 25 abstracts including Blenrep and Jemperli results
- HUTCHMED announced new and updated data from Ph II study of fruquintinib and surufatinib trials
- Imfinzi showed survival benefit in limited-stage SCLC in global Ph III trial, reducing the risk of death by 27% vs. placebo
- ImPact Biotech Presents Preliminary Ph 3 Results from ENLIGHTED Study of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer
- Indaptus Therapeutics Presents New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Ph 1 Trial of Decoy20
- Innate Pharma highlights five abstracts selected for publication
- Innovent Announces Taletrectinib Updated Data from Ph 2 TRUST-I Study
- Innovent Presents Ph 1 Data of IBI363 in Melanoma, Colorectal Cancer and other Solid Tumors
- Innovent Presents Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
- Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) + Keytruda Demonstrate Meaningful Clinical Activity in Ph 2 Trial in Patients with Previously Treated mNSCLC
- Ivonescimab Decisively Beats Pembrolizumab, Achieves Statistically Significant Superiority in PFS in 1L Treatment of Patients with PD-L1+ve NSCLC in China
- Jacobio Pharma Presents SHP2 + KRAS G12C Data
- Jazz Pharma Presents OS & Longer Follow-Up Data from HERIZON-BTC-01 Trial of Zanidatamab in Previously Treated HER2+ve BTC
- Johnson & Johnson presents more than 75 clinical study and real-world presentations
- Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 WT Endometrial Cancer
- KRAZATI (adagrasib) Demonstrated Statistically Significant PFS Improvement in Patients with Pretreated Locally Advanced/Metastatic KRASG12C-Mutated NSCLC
- Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
- Legend Biotech presents data from CARTITUDE-2 and -4 studies
- Mabwell Announces 9MW2821 Data and Latest Progress
- Merck to Present New Data Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
- Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
- Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab
- Nanobiotix Announces Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2L+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
- NeoTX Therapeutics presents preliminary results of naptumomab estafenatox (NAP) and docetaxel in phase 2 trial in patients with advanced/metastatic NSCLC
- Nimbus Therapeutics Presents New Positive Monotherapy Ph 1/2 Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors
- NKGen Biotech Publishes Ph 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors
- Novartis Scemblix Ph III data first to show superior efficacy with a favorable safety and tolerability profile vs. SoC TKIs in adults with newly diagnosed CML
- Nuvation Bio Announces Data from Pivotal Ph 2 TRUST-I Study of Taletrectinib
- Obsidian Therapeutics Announces Positive Data from OBX-115 in Patients with Advanced Melanoma
- Orca Bio Presents Positive Clinical Outcomes with Orca-T in Patients with AML
- Pacylex Pharmaceuticals Reports Zelenirstat Ph 1 safety and efficacy data
- Pfizer’s ADCETRIS Regimen Produces Clinically Meaningful Improvement in OS in Patients with R/R DLBCL
- Pfizer’s LORBRENA CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
- Puma Biotechnology Presented Findings from a Ph II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
- Purple Biotech Announces Positive Interim Randomized Ph 2 Data Demonstrating CM24 Improved OS and other Efficacy Endpoints in Pancreatic Cancer
- Rakuten Medical Announces Recent Interim Data from Ph 1b/2 Trial of ASP-1929 Photoimmunotherapy + anti-PD-1 for 1L Recurrent and/or Metastatic Head and Neck Cancer
- Regeneron presents Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) + Libtayo® (cemiplimab)
- RYBREVANT® (amivantamab-vmjw) + lazertinib showed longer PFS vs osimertinib in 1L treatment of patients with high-risk EGFR-mutated NSCLC
- Starpharma announces positive final DEP® irinotecan Ph 2 clinical trial results
- Takeda and Pfizer Announce 4-Year Results from Positive Ph 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combo in 1L Hodgkin Lymphoma
- TILT Biotherapeutics Presents Data on TILT-123 in Ovarian Cancer
- Ultimovacs ASA presents data from the Ph II trial INITIUM (NCT04382664)
- Updated Data from the Ph 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented
- VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Ph 2b Study of VBI-1901 in rGBM Patients
- Werewolf Therapeutics Presents Data from Ongoing Ph 1/1b Trial of WTX-124 as Monotherapy and in Combination with Keytruda in Solid Tumors
Menu
